Literature DB >> 19617708

Clinical development of malaria vaccines: should earlier trials be done in malaria endemic countries?

Roma Chilengi1.   

Abstract

Clinical development of malaria vaccines has had remarkable achievements in the past decade, but an efficacious vaccine is yet to be licensed. There are many scientific and technical challenges that hamper progress ranging from parasite to host to technical and to mere traditional convention factors. This paper outlines some of the key issues along the pathway and proposes the need for much earlier phase clinical research within Africa suggesting rationale and ethical justification for doing so. Challenge model studies could particularly be employed within malaria endemic country settings which may have critical advantages to complement the currently available sites in developed countries.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19617708     DOI: 10.4161/hv.9141

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  8 in total

Review 1.  Controlled Human Malaria Infection: Applications, Advances, and Challenges.

Authors:  Danielle I Stanisic; James S McCarthy; Michael F Good
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

Review 2.  Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in The Gambia: frontline challenges in study design and implementation.

Authors:  Muhammed O Afolabi; Jane U Adetifa; Egeruan B Imoukhuede; Nicola K Viebig; Beate Kampmann; Kalifa Bojang
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

Review 3.  Strengthening of the clinical research capacity for malaria: a shared responsibility.

Authors:  Charles S Mgone
Journal:  Malar J       Date:  2010-12-13       Impact factor: 2.979

4.  Anti-malarial market and policy surveys in sub-Saharan Africa.

Authors:  Graciela Diap; John Amuasi; Isaac Boakye; Ann-Marie Sevcsik; Bernard Pecoul
Journal:  Malar J       Date:  2010-04-23       Impact factor: 2.979

5.  Antiplasmodial activity of bacilosarcin A isolated from the octocoral-associated bacterium Bacillus sp. collected in Panama.

Authors:  Cristopher A Boya; Liuris Herrera; Hector M Guzman; Marcelino Gutierrez
Journal:  J Pharm Bioallied Sci       Date:  2012-01

6.  Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya.

Authors:  Susanne H Hodgson; Elizabeth Juma; Amina Salim; Charles Magiri; Daniel Njenga; Sassy Molyneux; Patricia Njuguna; Ken Awuondo; Brett Lowe; Peter F Billingsley; Andrew O Cole; Caroline Ogwang; Faith Osier; Roma Chilengi; Stephen L Hoffman; Simon J Draper; Bernhards Ogutu; Kevin Marsh
Journal:  Malar J       Date:  2015-04-28       Impact factor: 2.979

7.  "At first, I was very afraid"-a qualitative description of participants' views and experiences in the first Human Infection Study in Malawi.

Authors:  Neema Mtunthama Toto; Kate Gooding; Blessings M Kapumba; Kondwani Jambo; Jamie Rylance; Sarah Burr; Ben Morton; Stephen B Gordon; Lucinda Manda-Taylor
Journal:  Wellcome Open Res       Date:  2021-10-04

Review 8.  Experience and challenges from clinical trials with malaria vaccines in Africa.

Authors:  Grace Mwangoka; Bernhards Ogutu; Beverly Msambichaka; Tutu Mzee; Nahya Salim; Shubis Kafuruki; Maxmillian Mpina; Seif Shekalaghe; Marcel Tanner; Salim Abdulla
Journal:  Malar J       Date:  2013-03-04       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.